Alderyx.

Ardelyx GAAP EPS of -$0.13 misses by $0.03, revenue of $11.4M beats by $0.99M; Ardelyx resubmits NDA to FDA for tenapanor for chronic kidney disease; Ardelyx adds 16% as Wedbush upgrades after Q4 ...View the latest Ardelyx Inc. (ARDX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -25.98M. -347.29%. Get the latest Ardelyx Inc (ARDX) real-time quote, historical ...The FDA’s target action date is October 17. Ardelyx resubmitted its New Drug Application (NDA) in April 2023, providing data from a large development program with more than 1,200 patients enrolled across three Phase III trials: PHREEDOM, BLOCK and AMPLIFY. All studies met their primary and key secondary endpoints, pointing to the efficacy and ...

Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Apr 7, 2022 · Ardelyx is developing XPHOZAH ® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials ...

Ardelyx had cash, equivalents and investments totaling $90.6 million as of Sept. 30 and an accumulated deficit of $791 million. Largest Biopharma Companies in the Greater Bay Area Bay Area employeesJul 19, 2021 · Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company submitted an NDA to the FDA in June 2020.

Dec 29, 2022 · This is a momentous day for Ardelyx and for all the members of the broader kidney disease community who have supported the development of XPHOZAH over the past ten years," said Mike Raab ... Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin has received approval for PHOZEVEL ® …Ardelyx has an Altman Z-Score of 2.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Ardelyx, Inc. (ARDX) stock, including valuation metrics, financial numbers, share information and more.Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and reference call ... Jul 29, 2021 · Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...

WALTHAM, Mass., Nov. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class ...

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States , IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor) as well as early-stage pipeline candidates.

Ardelyx, Inc. manufactures biotechnological drugs. The Company offers pharmaceuticals to correct mineral metabolism imbalance and metabolic disorders by modulating the function of specific ...Ardelyx (ARDX) stock dropped 17% ahead of an expected FDA decision on its kidney disease drug Xphozah and amid news on Novo Nordisk's Ozempic in treating kidney failure.The average one-year price target for Ardelyx (NASDAQ:ARDX) has been revised to 9.84 / share. This is an increase of 6.30% from the prior estimate of 9.25 dated …The Alteryx Analytics Automation Platform delivers end-to-end automation of analytics, machine learning, and data science processes that accelerate digital ...Mike has served as Ardelyx’s President and Chief Executive Officer since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA), one of the world’s largest and most ...Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript October 31, 2023 Ardelyx, Inc. beats earnings expectations. Reported EPS is $0.02909, expectations were $-0.11. Operator: Good day and welcome to the Ardelyx Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I …

Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three …Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...Sep 3, 2021 · Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ... Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.Oct 20, 2022 · Ardelyx is developing XPHOZAH ® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials ... Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...

Jul 19, 2021 · Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company submitted an NDA to the FDA in June 2020. Conference call scheduled for 4:30 p.m. Eastern Time today. WALTHAM, Mass., Aug. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the second quarter ended June 30 ...

Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...WHO WE ARE. PRODUCTS. SCIENCE & PIPELINE. From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs.Ardelyx wants to offer chronic kidney disease patients a new, more convenient option for addressing a complication of their condition. The FDA on Thursday put a crimp in those plans, rejecting the ...Ardelyx (ARDX) is a specialized biopharmaceutical company focused on developing first-in-class, disruptive medicines for the treatment of renal diseases. The company's primary therapeutic focus is on treating people with renal diseases, which affect both the heart and the kidneys. This includes patients with end-stage renal disease, or …Alteryx Analytics is a tremendous platform allowing analysts to easily prep, blend, and analyze all their data using a repeatable workflow. Many business groups, such as marketing, finance, healthcare, and sales find it difficult to quickly analyze data they can act upon instantly using legacy approaches, such as Microsoft Excel and other platforms.Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...Sep 30, 2022 · Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx GAAP EPS of -$0.13 misses by $0.03, revenue of $11.4M beats by $0.99M; Ardelyx resubmits NDA to FDA for tenapanor for chronic kidney disease; Ardelyx adds 16% as Wedbush upgrades after Q4 ...Dec 29, 2022 · This is a momentous day for Ardelyx and for all the members of the broader kidney disease community who have supported the development of XPHOZAH over the past ten years," said Mike Raab ...

Ardelyx, Inc. May 3, 2023 at 1:02 PM · 11 min read. Ardelyx, Inc. Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million. XPHOZAH New Drug Application resubmitted on ...

U.S. Food and Drug Administration staff reviewers on Monday raised concerns over unclear benefits of Ardelyx Inc's drug for kidney disease patients, but the …

Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.May 17, 2023 · WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class... Calendar Ardelyx, Inc. Equities ARDX US0396971071 Market Closed - Nasdaq. Other stock markets. 01:00:00 2023-11-24 pm EST 5-day change 1st Jan Change 4.380 USD +1.62% +1.15% +53.68%: Nov. 13: Ardelyx Announces Departure of Geoffrey Block as Board Member CI ...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Alteryx is an end-to-end data analytics platform that allows users to prep, blend and analyze data in a drag and drop user interface. Drag and drop means that you …Nov 21, 2023. Ardelyx, Inc. Reports Employment Inducement Grants. Read More. Nov 21, 2023. Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference. Read More. Nov 15, 2023. XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia. Read More.Ardelyx is repurposing its first commercial product indicated for the treatment of Irritable Bowel Syndrome with Constipation in the U.S. and Canada. Read why ARDX is a buy.WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance Oct 30, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Oct 23, 2023 Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at …Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patientsOct 20, 2022 · Ardelyx is developing XPHOZAH ® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials ... Sep 3, 2021 · Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 ...

Sep 3, 2021 · Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 ... Third Quarter 2021 Financial Results. Cash Position: As of September 30, 2021, Ardelyx had total cash, cash equivalents and short-term investments of $141.7 million, as compared to total cash ...The FDA’s target action date is October 17. Ardelyx resubmitted its New Drug Application (NDA) in April 2023, providing data from a large development program with more than 1,200 patients enrolled across three Phase III trials: PHREEDOM, BLOCK and AMPLIFY. All studies met their primary and key secondary endpoints, pointing to the efficacy and ...Instagram:https://instagram. registered investment advisors houstonsteps to start day tradingconcreit real estate investingstock.market holidays SCIENCE & PIPELINE - Ardelyx. For decades, the gut had been under-recognized as a viable site for new therapeutic points of intervention for treating disease. Using our discovery model, which recreates environments within certain areas of the gastrointestinal tract and kidney, Ardelyx® scientists have been able to elucidate new and previously ... cruise tickercorning company Moventig is a medicine used in adults to treat constipation caused by pain relief medicines called opioids. It is used in patients in whom treatment with laxatives has failed. Moventig contains the active substance naloxegol. How is Moventig used? Moventig is available as tablets (12.5 and 25 mg). yieldstreet vs fundrise Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.Ardelyx Inc. Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases.